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All B cells need is BAFF
B cells usually conspire with T cells to break 
tolerance against the host and cause lupus. But 
Groom et al. (page 1959) now show that B 
cells don’t always need T cells to egg them on. 
An activating cytokine empowers them to cause 
trouble all on their own.
This cytokine, called BAFF (B cell–
activating factor), helps B cells survive as they 
transit through developmental checkpoints. 
BAFF also enhances T cell activation. With too 
much BAFF, however, even B cells that should 
have been eliminated—such as self-reactive 
ones—survive. The autoreactive antibodies 
first secreted by these cells are relatively harmless. But presumably 
with help from BAFF-activated T cells, these B cells switch their 
antibody genes and start producing pathogenic autoantibodies.
Groom et al. now find that the antibody-switching signal doesn’t 
have to come from T cells. Mice that overexpressed BAFF but lacked T cells still developed lupus. 
The B cells instead derived the extra push through their Toll-like receptors (TLRs) 7 and 9, whose 
expression was strongly enhanced by BAFF. The authors speculate that nucleic acids released by dying 
cells might trigger these TLRs on self-reactive B cells.
The presence of disease-inducing antibodies even when T cells are absent might explain why 
not all lupus patients respond to treatments that suppress T cell functions. The team is now 
investigating whether these patients have high levels of BAFF. 
EBV covers its tracks
Viruses that lie low inside cells after infection come under attack by the 
immune system when they reawaken and resume multiplying. Hislop 
et al. (page 1863) now reveal the mechanism used by the Epstein-Barr 
virus (EBV) to dodge host immunity during this reactivation phase.
EBV initially infects and replicates within oral epithelial cells but later 
quietly hides out in B cells. During this latent phase, EBV-infected B 
cells avoid the immune system by expressing very little viral antigen. To 
ensure viral spread and survival, however, EBV must reenter the 
replicative, or lytic, phase and invade new epithelial tissues.
Previous studies suggested that this herpesvirus also avoids the attention 
of the immune system during its reawakening. During the lytic phase, EBV-
infected B cells dial down the activity of their transporters associated with 
antigen processing (TAPs)—transmembrane channel proteins that shuttle 
antigenic peptides into the ER, where they find their HLA partners. Infected 
B cells thus display few viral antigens at the cell surface.
Known herpesviruses genes encoding TAP-inhibiting proteins were 
not found in the EBV genome. The authors therefore compared 
herpesvirus genomes to find a lytic phase TAP inhibitor gene in EBV and 
its closest relatives. Cloning and expression of candidate genes uncovered 
BNLF2a, which encodes a protein that blocked both the peptide-binding 
and ATP-binding sites on TAPs and thereby prevented it from translocating 
peptides into the ER.
This mechanism differs from those used by all other herpesvirus TAP 
inhibitors. The team is currently investigating how the relatively small 
BNLF2a protein blocks access to two distant sites on TAP. 
New mutations 
stabilize NOTCH1
A leukemia-associated signaling protein 
accumulates to dangerous levels when its own 
mutations shield it from degradation. Now, 
reports from O’Neil et al. (page 1813) and 
Thompson et al. (page 1825) identify outside 
forces that also lead to its buildup. Defects 
in proteasomal targeting, they find, can also 
trigger leukemia.
T cell acute 
lymphoblastic 
leukemia (T-ALL) 
is triggered by 
mutations in 
the NOTCH1 
receptor. Once 
activated, this transmembrane protein is clipped 
to release its intracellular domain (NICD), which 
then activates the transcription of genes that 
goad stem cells to become T cells.
Many transformed T cells have too much 
NICD, as their NOTCH1 proteins carry mutations 
that protect them from proteasomal 
degradation. This increase sends many NOTCH1 
targets, particularly oncogenes, into overdrive.
The new reports show that NICD levels are 
also high in some leukemic cell lines that lack 
NOTCH1 mutations. The defect in these cells 
lay instead in an enzyme called FBW7, which 
normally ubiquitinates NOTCH1 so it is 
recognized by the proteasome. The mutated 
version, which was also found in some T-ALL 
patients, failed to bind and ubiquitinate NICD.
Thompson et al. also found that the 
dysfunctional FBW7 did not bind some of its 
other targets, such as c-Myc and cyclin-E—
oncogenes that are turned on by NICD. This 
failure might account for the resistance of these 
cell lines to antileukemia drugs that prevent 
NOTCH1 receptor cleavage. 
Mutant versions of FBW7 from 
T-ALL patients don’t bind NICD.
Lupus-inducing B cells 
(arrows) develop even when 
T cells are missing (bottom).